Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
AssigneeOmeros Corporation
InventorsGregory A. Demopulos, Thomas A. Dudler
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
Claims62
A method of treating a human subject suffering from idiopathic pneumonia syndrome following hematopoietic stem cell transplant (HSCT-IPS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a human subject suffering from capillary leak syndrome following hematopoietic stem cell transplant (HSCT-CLS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a human subject suffering from fluid overload following hematopoietic stem cell transplant (HSCT-FO) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a human subject suffering from engraftment syndrome following hematopoietic stem cell transplant (HSCT-ES) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.